CellaVision AB (publ) (STO:CEVI)

Market Cap	4.44B
Revenue (ttm)	723.22M
Net Income (ttm)	140.72M
Shares Out	23.85M
EPS (ttm)	5.90
PE Ratio	31.53
Forward PE	26.11
Dividend	2.50 (1.34%)
Ex-Dividend Date	May 7, 2025

Volume	22,241
Average Volume	62,642
Open	186.80
Previous Close	187.20
Day's Range	185.40 - 190.20
52-Week Range	185.40 - 302.00
Beta	1.23
RSI	33.53
Earnings Date	Feb 6, 2025

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1994
• Employees: 228
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CEVI

Financial Performance

In 2024, CellaVision AB's revenue was 723.22 million, an increase of 6.78% compared to the previous year's 677.29 million. Earnings were 140.72 million, an increase of 7.99%.